

# David Blum

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/330763/david-blum-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

142  
papers

6,920  
citations

48  
h-index

81  
g-index

156  
ext. papers

8,251  
ext. citations

7.1  
avg. IF

5.54  
L-index

#	Paper	IF	Citations
142	Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. <i>Progress in Neurobiology</i> , <b>2001</b> , 65, 135-72	10.9	933
141	NLRP3 inflammasome activation drives tau pathology. <i>Nature</i> , <b>2019</b> , 575, 669-673	50.4	375
140	3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. <i>Journal of Neurochemistry</i> , <b>2005</b> , 95, 1521-40	6	289
139	Biochemistry of Tau in Alzheimer's disease and related neurological disorders. <i>Expert Review of Proteomics</i> , <b>2008</b> , 5, 207-24	4.2	197
138	Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?. <i>Biomedical Journal</i> , <b>2018</b> , 41, 21-33	7.1	161
137	Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment. <i>Anesthesiology</i> , <b>2012</b> , 116, 779-87	4.3	157
136	Targeting phospho-Ser422 by active Tau Immunotherapy in the THY Tau22 mouse model: a suitable therapeutic approach. <i>Current Alzheimer Research</i> , <b>2012</b> , 9, 397-405	3	153
135	Clinical potential of minocycline for neurodegenerative disorders. <i>Neurobiology of Disease</i> , <b>2004</b> , 17, 359-66	7.5	134
134	Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid- $\beta$ -42 oligomers are revealed in vivo by using a novel animal model. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 7852-61	6.6	130
133	Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 2079-90	5.6	117
132	Tau deletion promotes brain insulin resistance. <i>Journal of Experimental Medicine</i> , <b>2017</b> , 214, 2257-2269	16.6	114
131	Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. <i>Lancet Neurology</i> , <b>2003</b> , 2, 366-74	24.1	113
130	Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. <i>Brain</i> , <b>2017</b> , 140, 184-200	11.2	112
129	Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. <i>Neurobiology of Disease</i> , <b>2011</b> , 43, 486-94	7.5	111
128	Premature ovarian aging in mice deficient for Gpr3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 8922-6	11.5	111
127	Atypical, non-standard functions of the microtubule associated Tau protein. <i>Acta Neuropathologica Communications</i> , <b>2017</b> , 5, 91	7.3	110
126	Altered neuronal excitability in cerebellar granule cells of mice lacking calretinin. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 9320-7	6.6	106

125	A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 5361-9	6.6	105
124	p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. <i>Brain Research</i> , <b>1997</b> , 751, 139-42	3.7	99
123	A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. <i>Molecular Psychiatry</i> , <b>2016</b> , 21, 97-107	15.1	94
122	Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. <i>Progress in Neurobiology</i> , <b>2007</b> , 81, 331-48	10.9	94
121	Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 2474-2478	5.6	91
120	Extracellular toxicity of 6-hydroxydopamine on PC12 cells. <i>Neuroscience Letters</i> , <b>2000</b> , 283, 193-6	3.3	87
119	Novel Alzheimer risk genes determine the microglia response to amyloid- $\beta$ but not to TAU pathology. <i>EMBO Molecular Medicine</i> , <b>2020</b> , 12, e10606	12	86
118	Detrimental effects of diet-induced obesity on $\beta$ pathology are independent of insulin resistance in $\beta$ transgenic mice. <i>Diabetes</i> , <b>2013</b> , 62, 1681-8	0.9	80
117	Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. <i>Scientific Reports</i> , <b>2015</b> , 5, 9659	4.9	73
116	Age-related shift in LTD is dependent on neuronal adenosine A receptors interplay with mGluR5 and NMDA receptors. <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 1876-1900	15.1	71
115	From tau phosphorylation to tau aggregation: what about neuronal death?. <i>Biochemical Society Transactions</i> , <b>2010</b> , 38, 967-72	5.1	70
114	Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. <i>Neurobiology of Learning and Memory</i> , <b>2011</b> , 95, 296-304	3.1	69
113	The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 19296-304	5.4	69
112	The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. <i>Journal of Neuroscience</i> , <b>2002</b> , 22, 9122-33	6.6	68
111	Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 5965-76	5.6	67
110	Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. <i>Frontiers in Molecular Neuroscience</i> , <b>2018</b> , 11, 2	6.1	67
109	The Chemokine MIP-1 $\beta$ /CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. <i>Scientific Reports</i> , <b>2015</b> , 5, 15862	4.9	67
108	A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. <i>Neurobiology of Disease</i> , <b>2009</b> , 35, 474-6	7.5	67

107	Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease. <i>Molecular and Cellular Neurosciences</i> , <b>2008</b> , 37, 454-70	4.8	66
106	D-Hydroxybutyrate is protective in mouse models of Huntington's disease. <i>PLoS ONE</i> , <b>2011</b> , 6, e24620	3.7	65
105	Dysregulation of TrkB Receptors and BDNF Function by Amyloid- $\beta$ Peptide is Mediated by Calpain. <i>Cerebral Cortex</i> , <b>2015</b> , 25, 3107-21	5.1	59
104	A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. <i>Current Pharmaceutical Design</i> , <b>2008</b> , 14, 1500-11	3.3	58
103	Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2007</b> , 66, 363-71	3.1	56
102	NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. <i>Aging Cell</i> , <b>2013</b> , 12, 11-23	9.9	55
101	Mutant huntingtin alters Tau phosphorylation and subcellular distribution. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 76-85	5.6	53
100	Association between caffeine intake and age at onset in Huntington's disease. <i>Neurobiology of Disease</i> , <b>2013</b> , 58, 179-82	7.5	51
99	Worsening of Huntington disease phenotype in CB1 receptor knockout mice. <i>Neurobiology of Disease</i> , <b>2011</b> , 42, 524-9	7.5	51
98	Effects of remifentanyl on N-methyl-D-aspartate receptor: an electrophysiologic study in rat spinal cord. <i>Anesthesiology</i> , <b>2005</b> , 102, 1235-41	4.3	51
97	Minocycline in phenotypic models of Huntington's disease. <i>Neurobiology of Disease</i> , <b>2005</b> , 18, 206-17	7.5	50
96	Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. <i>Neurobiology of Disease</i> , <b>2004</b> , 15, 152-9	7.5	49
95	Deregulation of neuronal miRNAs induced by amyloid- $\beta$ or TAU pathology. <i>Molecular Neurodegeneration</i> , <b>2018</b> , 13, 54	19	48
94	Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. <i>Transfusion Medicine</i> , <b>2010</b> , 20, 48-61	1.3	46
93	Beneficial Effect of a Selective Adenosine A Receptor Antagonist in the APP <sup>swe</sup> /PS1 <sup>dE9</sup> Mouse Model of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , <b>2018</b> , 11, 235	6.1	45
92	Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. <i>Neurobiology of Disease</i> , <b>2002</b> , 10, 410-26	7.5	45
91	Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. <i>NeuroReport</i> , <b>2001</b> , 12, 1769-72	1.7	44
90	Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 552-5	5.5	43

89	Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. <i>Experimental Neurology</i> , <b>2007</b> , 204, 387-99	5.7	42
88	A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , <b>2011</b> , 41, 570-6	7.5	40
87	Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease. <i>Current Alzheimer Research</i> , <b>2009</b> , 6, 152-7	3	40
86	The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function. <i>Scientific Reports</i> , <b>2016</b> , 6, 31493	4.9	38
85	Unlike MPP+, apoptosis induced by 6-OHDA in PC12 cells is independent of mitochondrial inhibition. <i>Neuroscience Letters</i> , <b>1996</b> , 221, 69-71	3.3	38
84	6-hydroxydopamine-induced nuclear factor-kappa B activation in PC12 cells. <i>Biochemical Pharmacology</i> , <b>2001</b> , 62, 473-81	6	37
83	Nuclear factor-kappa B activation in permanent intraluminal focal cerebral ischemia in the rat. <i>Neuroscience Letters</i> , <b>2000</b> , 288, 241-5	3.3	37
82	Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain. <i>Neuropharmacology</i> , <b>2005</b> , 49, 695-702	5.5	35
81	Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. <i>Brain</i> , <b>2019</b> , 142, 3636-3654	11.2	34
80	From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?. <i>Biochemical Society Transactions</i> , <b>2014</b> , 42, 587-92	5.1	34
79	Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 181	4.1	34
78	Rescue of impaired late-phase long-term depression in a tau transgenic mouse model. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 730-9	5.6	33
77	Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	33
76	Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , <b>2018</b> , 55, 8936-8952	6.2	32
75	Progressive age-related cognitive decline in tau mice. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 37, 777-88	4.3	29
74	Loss of medial septum cholinergic neurons in THY-Tau22 mouse model: what links with tau pathology?. <i>Current Alzheimer Research</i> , <b>2011</b> , 8, 633-8	3	29
73	Amyloid and tau neuropathology differentially affect prefrontal synaptic plasticity and cognitive performance in mouse models of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 37, 109-25	4.3	25
72	PTU-induced hypothyroidism in rats leads to several early neuropathological signs of Alzheimer's disease in the hippocampus and spatial memory impairments. <i>Hippocampus</i> , <b>2014</b> , 24, 1381-93	3.5	25

71	The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease. <i>Journal of Caffeine and Adenosine Research</i> , <b>2018</b> , 8, 43-58	1.6	25
70	Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor. <i>Transfusion</i> , <b>2012</b> , 52, 1721-8	2.9	23
69	Increased tauopathy drives microglia-mediated clearance of beta-amyloid. <i>Acta Neuropathologica Communications</i> , <b>2016</b> , 4, 63	7.3	23
68	Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains. <i>Brain Research</i> , <b>2010</b> , 1345, 182-9	3.7	22
67	Lack of minocycline efficiency in genetic models of Huntington's disease. <i>NeuroMolecular Medicine</i> , <b>2007</b> , 9, 47-54	4.6	22
66	Mutual Relationship between Tau and Central Insulin Signalling: Consequences for AD and Tauopathies?. <i>Neuroendocrinology</i> , <b>2018</b> , 107, 181-195	5.6	20
65	Increased Alix (apoptosis-linked gene-2 interacting protein X) immunoreactivity in the degenerating striatum of rats chronically treated by 3-nitropropionic acid. <i>Neuroscience Letters</i> , <b>2004</b> , 368, 309-13	3.3	20
64	The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , <b>2018</b> , 12, 520	5.1	19
63	Thyroid Hormone Supplementation Restores Spatial Memory, Hippocampal Markers of Neuroinflammation, Plasticity-Related Signaling Molecules, and $\beta$ Amyloid Peptide Load in Hypothyroid Rats. <i>Molecular Neurobiology</i> , <b>2019</b> , 56, 722-735	6.2	17
62	Observations in THY-Tau22 mice that resemble behavioral and psychological signs and symptoms of dementia. <i>Behavioural Brain Research</i> , <b>2013</b> , 242, 34-9	3.4	17
61	Association of corticobasal degeneration and Huntington's disease: can Tau aggregates protect Huntingtin toxicity?. <i>Movement Disorders</i> , <b>2009</b> , 24, 1089-90	7	15
60	A R-induced transcriptional deregulation in astrocytes: An in vitro study. <i>Glia</i> , <b>2019</b> , 67, 2329-2342	9	14
59	Dual role of MUC1 mucin in kidney ischemia-reperfusion injury: Nephroprotector in early phase, but pro-fibrotic in late phase. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2017</b> , 1863, 1336-1349	6.9	13
58	Aging, but not tau pathology, impacts olfactory performances and somatostatin systems in THY-Tau22 mice. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 1013-28	5.6	13
57	Minocycline-induced activation of tetracycline-responsive promoter. <i>Neuroscience Letters</i> , <b>2003</b> , 352, 155-8	3.3	13
56	Clearance of manganese from the rat substantia nigra following intra-nigral microinjections. <i>Neuroscience Letters</i> , <b>2002</b> , 328, 170-4	3.3	13
55	New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. <i>Neurobiology of Disease</i> , <b>2019</b> , 129, 217-233	7.5	11
54	Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. <i>Archives of Toxicology</i> , <b>2018</b> , 92, 1539-1550	5.8	11

53	The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. <i>Journal of Biomedical Science</i> , <b>2019</b> , 26, 89	13.3	11
52	Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 757-69	5.6	11
51	Hippocampal BDNF expression in a tau transgenic mouse model. <i>Current Alzheimer Research</i> , <b>2012</b> , 9, 406-10	3	11
50	Chronic intoxication with 3-nitropropionic acid in rats induces the loss of striatal dopamine terminals without affecting nigral cell viability. <i>Neuroscience Letters</i> , <b>2004</b> , 354, 234-8	3.3	11
49	IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease. <i>Cell Reports</i> , <b>2021</b> , 36, 109574	10.6	10
48	Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 1725-1736	4.3	9
47	Caffeine Consumption During Pregnancy Accelerates the Development of Cognitive Deficits in Offspring in a Model of Tauopathy. <i>Frontiers in Cellular Neuroscience</i> , <b>2019</b> , 13, 438	6.1	8
46	Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. <i>Neurobiology of Disease</i> , <b>2019</b> , 125, 14-22	7.5	8
45	Design, synthesis and evaluation of 2-aryl benzoxazoles as promising hit for the A receptor. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2017</b> , 32, 850-864	5.6	8
44	Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1184, 207-216	3.6	8
43	Omics analysis of mouse brain models of human diseases. <i>Gene</i> , <b>2017</b> , 600, 90-100	3.8	7
42	Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation. <i>Platelets</i> , <b>2021</b> , 32, 226-237	3.6	7
41	Chronic Sodium Selenate Treatment Restores Deficits in Cognition and Synaptic Plasticity in a Murine Model of Tauopathy. <i>Frontiers in Molecular Neuroscience</i> , <b>2020</b> , 13, 570223	6.1	6
40	Consensus brain-derived protein, extraction protocol for the study of human and murine brain proteome using both 2D-DIGE and mini 2DE immunoblotting. <i>Journal of Visualized Experiments</i> , <b>2014</b> ,	1.6	6
39	Neuronal tau species transfer to astrocytes and induce their loss according to tau aggregation state. <i>Brain</i> , <b>2021</b> , 144, 1167-1182	11.2	6
38	Glial cells and adaptive immunity in frontotemporal dementia with tau pathology. <i>Brain</i> , <b>2021</b> , 144, 724-745	11.2	6
37	Brain network remodelling reflects tau-related pathology prior to memory deficits in Thy-Tau22 mice. <i>Brain</i> , <b>2020</b> , 143, 3748-3762	11.2	5
36	The Controversial Role of Adenosine A2A Receptor Antagonists as Neuro-protective Agents. <i>Current Medicinal Chemistry - Central Nervous System Agents</i> , <b>2004</b> , 4, 35-45		5

35	Glial Purinergic Signaling in Neurodegeneration. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 654850	4.1	5
34	Hyperexcitability and seizures in the THY-Tau22 mouse model of tauopathy. <i>Neurobiology of Aging</i> , <b>2020</b> , 94, 265-270	5.6	4
33	MRNA Levels of ACh-Related Enzymes in the Hippocampus of THY-Tau22 Mouse: A Model of Human Tauopathy with No Signs of Motor Disturbance. <i>Journal of Molecular Neuroscience</i> , <b>2016</b> , 58, 411-33	3.3	4
32	Tau protein: function and pathology. <i>International Journal of Alzheimers Disease</i> , <b>2012</b> , 2012, 707482	3.7	4
31	Recombinant AAV Viral Vectors Serotype 1, 2, and 5 Mediate Differential Gene Transfer Efficiency in Rat Striatal Fetal Grafts. <i>Cell Transplantation</i> , <b>2007</b> , 16, 1013-1020	4	4
30	Does physical activity associated with chronic food restriction alleviate anxiety like behaviour, in female mice?. <i>Hormones and Behavior</i> , <b>2020</b> , 124, 104807	3.7	4
29	Mort neuronale dans les modèles expérimentaux de la maladie de Parkinson. <i>Medecine/Sciences</i> , <b>2002</b> , 18, 457-466		3
28	Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment. <i>Brain</i> , <b>2021</b> , 144, 3142-3158	11.2	3
27	P2X7-deficiency improves plasticity and cognitive abilities in a mouse model of Tauopathy. <i>Progress in Neurobiology</i> , <b>2021</b> , 206, 102139	10.9	3
26	Early-Life Environment Influence on Late-Onset Alzheimer's Disease.. <i>Frontiers in Cell and Developmental Biology</i> , <b>2022</b> , 10, 834661	5.7	3
25	What Is the Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease? <b>2018</b> , 281-308		2
24	Adenosine Receptors and Alzheimer's Disease <b>2013</b> , 385-407		2
23	Citicoline is not protective in experimental models of Huntington's disease. <i>Neurobiology of Aging</i> , <b>2007</b> , 28, 1944-6	5.6	2
22	A cautionary note on the use of stable transformed cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2000</b> , 5, 115-6	5.4	2
21	Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. <i>Acta Neuropathologica Communications</i> , <b>2021</b> , 9, 112	7.3	2
20	THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiency. <i>Neurobiology of Disease</i> , <b>2021</b> , 155, 105398	7.5	2
19	Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines. <i>European Journal of Medicinal Chemistry</i> , <b>2015</b> , 106, 15-25	6.8	1
18	Adenosine Receptors in Huntington's Disease <b>2013</b> , 409-434		1



17	C08 Caffeine is a modifier of age at onset in Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2010</b> , 81, A18.2-A18	5.5	1
16	RLU and studies using the luciferase reporter gene. <i>Nature Biotechnology</i> , <b>1998</b> , 16, 702	44.5	1
15	Overexpression of mouse IsK protein fused to green fluorescent protein induces apoptosis of human astrogloma cells. <i>Neurological Research</i> , <b>2007</b> , 29, 628-31	2.7	1
14	Minocycline-induced activation of tetracycline-responsive promoter. <i>Neuroscience Letters</i> , <b>2003</b> ,	3.3	1
13	In situ examination of tyrosine hydroxylase activity in the rat locus coeruleus using (3',5')-[(3)H(2)]-alpha-fluoromethyl-tyrosine as substrate of the enzyme. <i>Synapse</i> , <b>2000</b> , 35, 201-11	2.4	1
12	Stabilizing synapses. <i>Science</i> , <b>2021</b> , 374, 684-685	33.3	1
11	Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine. <i>ACS Biomaterials Science and Engineering</i> , <b>2021</b> ,	5.5	1
10	Tau, Diabetes and Insulin. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1184, 259-287	3.6	1
9	Novel Alzheimer risk genes determine the microglia response to amyloid- $\beta$ but not to TAU pathology		1
8	A $\beta$ Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 679335	5.6	0
7	Impact of chronic doxycycline treatment in the APP/PS1 mouse model of Alzheimer's disease.. <i>Neuropharmacology</i> , <b>2022</b> , 209, 108999	5.5	0
6	Mammalian Brain Ca <sup>2+</sup> Channel Activity Transplanted into <i>Xenopus laevis</i> Oocytes. <i>Membranes</i> , <b>2022</b> , 12, 496	3.8	0
5	Adenosine Receptors and Memory Disorders <b>2017</b> , 175-186		
4	Adenosine: A Complex Role in Neurodegeneration. <i>Journal of Caffeine and Adenosine Research</i> , <b>2019</b> , 9, 71-72	1.6	
3	Mycoplasmas as gene therapy vectors?. <i>Nature Biotechnology</i> , <b>1999</b> , 17, 4	44.5	
2	Tau- but not A $\beta$ pathology enhances NMDAR-dependent depotentiation in AD-mouse models. <i>Acta Neuropathologica Communications</i> , <b>2019</b> , 7, 202	7.3	
1	Impaired Glucose Homeostasis in a Tau Knock-In Mouse Model.. <i>Frontiers in Molecular Neuroscience</i> , <b>2022</b> , 15, 841892	6.1	